SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Aspen Pharmacare Holdings Limited (APNHF) , forward earnings yield 116.28%. PEG 0.06 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 0.9
- PEG Ratio 0.06 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 46/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — APNHF
Valuation Multiples
P/E (TTM)0.0
Forward P/E0.9
PEG Ratio0.06
Forward PEG0.06
P/B Ratio0.00
P/S Ratio0.09
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.44
Forward EPS (Est.)$10.07
Book Value / Share$0.00
Revenue / Share$97.66
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield116.28%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$9.45 |
$35.6B |
$4.3B |
12.1% |
| 2017 |
$11.23 |
$41.21B |
$5.13B |
12.4% |
| 2018 |
$13.23 |
$38.31B |
$6.04B |
15.8% |
| 2019 |
$14.16 |
$38.87B |
$6.46B |
16.6% |
| 2020 |
$10.22 |
$38.65B |
$4.66B |
12.1% |
| 2021 |
$10.53 |
$37.77B |
$4.81B |
12.7% |
| 2022 |
$14.32 |
$38.61B |
$6.49B |
16.8% |
| 2023 |
$11.77 |
$40.71B |
$5.23B |
12.8% |
| 2024 |
$9.91 |
$44.71B |
$4.4B |
9.9% |
| 2025 |
$-2.44 |
$43.36B |
$-1.08B |
-2.5% |
